These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 32418466)

  • 1. Disseminated intravascular coagulation in advanced lung adenocarcinoma during first-line pembrolizumab.
    Alberti A; Mancin M; Cortinovis D; Bidoli P; Sala L
    Immunotherapy; 2020 Jun; 12(9):629-633. PubMed ID: 32418466
    [No Abstract]   [Full Text] [Related]  

  • 2. Dramatic, significant metabolic response to a one-time pembrolizumab treatment following a relapse of pre-existing organizing pneumonia in a patient with advanced non-small cell lung cancer: A case report.
    Kato M; Mori M; Miura K; Asao T; Motomura H; Nishino K; Ko R; Koyama R; Hayashi T; Takahashi K
    Thorac Cancer; 2021 Nov; 12(22):3076-3079. PubMed ID: 34617405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report.
    Sugano T; Seike M; Funasaka Y; Yoshida M; Takayama R; Okamura K; Nakanishi A; Tanaka T; Takeuchi S; Noro R; Minegishi Y; Kubota K; Saeki H; Gemma A
    J Immunother Cancer; 2019 Feb; 7(1):59. PubMed ID: 30813943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholestatic Liver Injury Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma.
    Kurokawa K; Hara M; Iwakami SI; Genda T; Iwakami N; Miyashita Y; Fujioka M; Sasaki S; Takahashi K
    Intern Med; 2019; 58(22):3283-3287. PubMed ID: 31735738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pembrolizumab-induced vitiligo in a patient with lung adenocarcinoma: A case report.
    Bulat V; Likic R; Bradic L; Speeckaert R; Azdajic MD
    Br J Clin Pharmacol; 2021 Jun; 87(6):2614-2618. PubMed ID: 33217043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Invasive Pulmonary Aspergillosis Complicated by Carbapenem-Resistant Pseudomonas aeruginosa Infection During Pembrolizumab Immunotherapy for Metastatic Lung Adenocarcinoma: Case Report and Review of the Literature.
    Oltolini C; Ripa M; Andolina A; Brioschi E; Cilla M; Petrella G; Gregorc V; Castiglioni B; Tassan Din C; Scarpellini P
    Mycopathologia; 2019 Feb; 184(1):181-185. PubMed ID: 30101407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
    Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
    Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pericardial tamponade during pembrolizumab treatment in a patient with advanced lung adenocarcinoma: A case report and review of the literature.
    Harada K; Ogasawara M; Shido A; Meno A; Oda S; Yoshida S; Yoshida S; Yoshikawa A; Ebata K; Abiko S; Kawagishi N; Sano I; Oda H; Miyagishima T
    Thorac Cancer; 2020 May; 11(5):1350-1353. PubMed ID: 32181993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three cases of immune cholangitis related to anti-programmed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer.
    Fouchard M; Jantzem H; Quere G; Descourt R; Robinet G; Poureau PG
    Eur J Cancer; 2019 Jul; 115():107-110. PubMed ID: 31132740
    [No Abstract]   [Full Text] [Related]  

  • 10. Real-World Efficacy of First-Line Pembrolizumab in Patients With Advanced or Recurrent Non-Small-Cell Lung Cancer and High PD-L1 Tumor Expression.
    Tambo Y; Sone T; Shibata K; Nishi K; Shirasaki H; Yoneda T; Araya T; Kase K; Nishikawa S; Kimura H; Kasahara K
    Clin Lung Cancer; 2020 Sep; 21(5):e366-e379. PubMed ID: 32199806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab induced toxic epidermal necrolysis.
    Kumar R; Bhandari S
    Curr Probl Cancer; 2020 Apr; 44(2):100478. PubMed ID: 31122669
    [No Abstract]   [Full Text] [Related]  

  • 12. Non-bacterial cystitis caused by pembrolizumab therapy for adenocarcinoma of the lung: a case report.
    Di C; Yu T; Ni L
    Front Immunol; 2024; 15():1423123. PubMed ID: 39034999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuropsychiatric Immune-related Adverse Events Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma and Systemic Lupus Erythematosus.
    Jono M; Kinehara Y; Utsu Y; Tamura Y; Koseto M; Murakami T; Uota A; Ninomiya R; Komo S; Sumitani S; Sato B; Kasayama S; Tachibana I
    Intern Med; 2020 Feb; 59(4):569-572. PubMed ID: 31666468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Life threatening pembrolizumabinduced myositis in a patient treated for advanced adenocarcinoma of the lung.
    Robinson SD; Lai C; Hotton G; Anand G
    Acute Med; 2019; 18(3):197-199. PubMed ID: 31536059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psoriatic arthritis induced by anti-programmed death 1 antibody pembrolizumab.
    Hara T; Mikita N; Ikeda T; Inaba Y; Kunimoto K; Kaminaka C; Kanazawa N; Yamamoto Y; Jinnin M
    J Dermatol; 2019 Dec; 46(12):e466-e467. PubMed ID: 31376178
    [No Abstract]   [Full Text] [Related]  

  • 16. Compromise or not? A case report of successful treatment of pembrolizumab-induced hepatitis in a patient with non-small cell lung cancer with low-dose methylprednisolone and bicyclol.
    Liu Y; Zhang J; Yin Z; Zhu X; Xue L; Cao B
    Thorac Cancer; 2020 Jul; 11(7):2023-2030. PubMed ID: 32379397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxic epidermal necrolysis associated with pembrolizumab.
    Cai ZR; Lecours J; Adam JP; Marcil I; Blais N; Dallaire M; Belisle A; Mathieu A
    J Oncol Pharm Pract; 2020 Jul; 26(5):1259-1265. PubMed ID: 31810421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pembrolizumab-related Immune Thrombocytopenia in a Patient with Lung Adenocarcinoma Treated by Radiotherapy: Potential Immune-related Adverse Event Elicited by Radiation Therapy.
    Tamanoi D; Saruwatari K; Imamura K; Sato R; Jodai T; Hamada S; Tomita Y; Saeki S; Ueno S; Yonemura Y; Ichiyasu H; Sakagami T
    Intern Med; 2022 Jun; 61(11):1731-1734. PubMed ID: 34776479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opportunistic bowel infection after corticosteroid dosage tapering in a stage IV lung cancer patient with tislelizumab-related colitis.
    Ni J; Zhang X; Zhang L
    Thorac Cancer; 2020 Jun; 11(6):1699-1702. PubMed ID: 32239681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case report: reinitiating pembrolizumab treatment after small bowel perforation.
    Beck TN; Kudinov AE; Dulaimi E; Boumber Y
    BMC Cancer; 2019 Apr; 19(1):379. PubMed ID: 31018834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.